Special Issue

Molecular Mechanism for Coronavirus Infection

Message from the Guest Editor

As we are going to enter year 4 of the coronavirus pandemic, much progress has been made in developing prophylaxis and therapeutic agents against coronavirus infection. However, there are still many actual problems in the field of molecular mechanisms for coronavirus infection. Of them, the underlying molecular mechanism responsible for the high level of viral transmissibility and broad tissue tropism or interspecies transmission remains largely unexplored; the characterization of the coronavirus infection process, as well as viral and host factors that are involved in the pathogenesis of viral infection; the development of novel or repurposed prophylaxis and therapeutic agents targeting hostpathogen interaction; the molecular mechanism underlying the waning effectiveness of COVID vaccines or drugs and possible viral breakthrough infections and immune evasion, etc., warrant further investigation. For this Special Issue, we are seeking original research or review articles that will improve our knowledge of these topics mentioned above.

Guest Editor

Dr. Qibin Geng

Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

closed (31 October 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/150049

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/ biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health. Boston. MA 02115. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).